Semaglutide Injection Once-Weekly for Weight Management in Adults: Results From A Randomized Phase III, Active-Controlled Study

Ambika Gopalakrishnan U, Joshi A, Kumar H, et al.

Diabetes, obesity & metabolism, 2026

Potential role of tirzepatide, a dual GLP-1 and GIP receptor agonist, for preventive treatment of migraine: A case series

Shah T, Dougherty C, Ailani J, et al.

Headache, 2026

Protocol for Novel Perioperative Optimization of Obese Osteoarthritic Patients pending Total Knee Replacement with glucagon-like peptide-1 receptor agonist (NPO-OOPS-TKR) : a pilot randomized controlled trial

Lau LCM, Lui TWD, Wen C, et al.

Bone & joint open, 2026;7(7):861-870

GLP-1 Receptor Agonists for Weight Loss and Risk of Major Safety Outcomes: A Multicentre Cohort Study

Park J, Kim JH, Kim YS, et al.

Diabetes, obesity & metabolism, 2026

A Sequential Dual GLP-1R/GIPR Agonist-To-Antagonist Molecule Achieves Superior Weight Loss in Obese Mice

Zhang Y, Zhu B, Peng B, et al.

Diabetes, obesity & metabolism, 2026

Real-World Effectiveness and Safety of Tirzepatide in Type 1 Diabetes and Obesity: Impact on Glycaemia, Weight, and Cardiometabolic Risk Markers

Berry SA, Goodman IR, McNally E, et al.

Diabetes, obesity & metabolism, 2026

Comment on ‘The Impact of Missed Doses on Pharmacokinetic Concentrations for Oral Semaglutide in Comparison to Other Glucagon-Like Peptide-1-Based Therapies’

Bao J, Wang M

Diabetes, obesity & metabolism, 2026

Cardiovascular Outcomes With Tirzepatide Versus GLP-1 Receptor Agonists in Overweight or Obesity: A Systematic Review and Meta-Analysis

Silva JPMRJ, Nogueira BV, Sartori DL, et al.

Diabetes, obesity & metabolism, 2026

Gallbladder-Related Adverse Events With Semaglutide 2.4 mg: Pooled Analysis of Placebo-Controlled STEP Trials

Ukkonen M, Kivivuori A, Starckjohann P, et al.

Diabetes, obesity & metabolism, 2026

Correction to: “Atypical retrobulbar optic neuropathy after semaglutide escalation”

JCEM case reports, 2026;4(8):luag179

Correction: Exploring factors predicting the effectiveness of oral semaglutide in Japanese individuals with type 2 diabetes switching from dipeptidyl peptidase 4 inhibitors: a pilot study

Hirotsu T, Taniguchi K, Nishimura R

Frontiers in clinical diabetes and healthcare, 2026;7:1914250

Tirzepatide and metabolic dysfunction-associated steatotic liver disease (MASLD) in obesity: a real-world multicenter study

Galasso M, Verde L, Patrone R, et al.

Frontiers in endocrinology, 2026;17:1855886

Fabrication and characterization of biocompatible BPC-157 based chitosan hydrogel

Arunim, Dagar M, Solanki M, et al.

3 Biotech, 2026;16(8):312

From Weight Loss to Organ-Specific Disease Modification: A Narrative Review of Incretin-Based Therapies in Obesity-Related Cardiometabolic Disease, Chronic Kidney Disease, Metabolic Dysfunction-Associated Steatohepatitis, and Obstructive Sleep Apnoea

Joshi D

Cureus, 2026;18(7):e112135

Novel cutaneous adverse effects of the increasingly prevalent glucagon-like peptide 1 agonists

Carson L, Eisner M, Launay C, et al.

Skin health and disease, 2026;6(5):808-811

Letter: Non-Invasive Tests After Semaglutide in MASH as Disease-Activity Readouts Rather Than Response Biomarkers

Mao G, Lan H

Alimentary pharmacology & therapeutics, 2026

Overcoming Gastric Barriers for Oral Peptide Delivery: QbD-Based Development of Sodium Caprate-Enabled Tirzepatide Tablets

Im S, Lee JY, Kim JE

Pharmaceutics, 2026;18(7)

Quantitative MRI Pharmacokinetic Modeling and MALDI Mass Spectrometry Imaging Biodistribution of a pH Mapping MRI Contrast Agent

Mohanta Z, Tressler CM, Gori S, et al.

Theranostics, 2026;16(14):7937-7957

Effect of GLP-1RA on blood eosinophil levels in adults: a real-world study

Wu Y, Lin Y, Wu J, et al.

BMC pulmonary medicine, 2026

GLP-1 receptor agonists in pediatric obesity

Abodi M, Agostoni CV, Mazzocchi A

Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2026